End­ing four years of le­gal fight, ARCH-backed syn­thet­ic DNA mak­er set­tles law­suit with CEO's for­mer em­ploy­er

When Twist Bio­science filed for an IPO in 2018, one is­sue fea­tured promi­nent­ly in the sec­tions where ex­ecs warned in­vestors about the risks re­lat­ed to their syn­thet­ic DNA busi­ness.

We and our chief ex­ec­u­tive of­fi­cer are cur­rent­ly in­volved in lit­i­ga­tion with Ag­i­lent in which Ag­i­lent has al­leged a claim of trade se­cret mis­ap­pro­pri­a­tion against our Com­pa­ny and trade se­cret mis­ap­pro­pri­a­tion and oth­er re­lat­ed claims against our chief ex­ec­u­tive of­fi­cer. This lit­i­ga­tion with Ag­i­lent could re­sult in sig­nif­i­cant ex­pense. Ag­i­lent has con­sid­er­able re­sources avail­able to it; we, on the oth­er hand, are an ear­ly-stage com­mer­cial com­pa­ny with com­par­a­tive­ly few re­sources avail­able to us to en­gage in cost­ly and pro­tract­ed lit­i­ga­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER